Qube Research & Technologies Ltd purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 738 shares of the medical research company’s stock, valued at approximately $231,000.

Several other large investors have also recently modified their holdings of BIO. American Century Companies Inc. lifted its position in shares of Bio-Rad Laboratories by 14.7% in the 1st quarter. American Century Companies Inc. now owns 788,955 shares of the medical research company’s stock valued at $241,168,000 after acquiring an additional 100,850 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Bio-Rad Laboratories by 197.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 66,203 shares of the medical research company’s stock worth $20,237,000 after buying an additional 43,964 shares in the last quarter. Tygh Capital Management Inc. purchased a new stake in Bio-Rad Laboratories in the 1st quarter worth approximately $12,812,000. WINTON GROUP Ltd purchased a new stake in Bio-Rad Laboratories in the 2nd quarter worth approximately $13,083,000. Finally, Intermede Investment Partners Ltd lifted its position in Bio-Rad Laboratories by 42.7% in the 1st quarter. Intermede Investment Partners Ltd now owns 116,175 shares of the medical research company’s stock worth $35,512,000 after buying an additional 34,779 shares in the last quarter. Institutional investors and hedge funds own 61.95% of the company’s stock.

In other news, EVP Timothy S. Ernst sold 310 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $320.00, for a total transaction of $99,200.00. Following the transaction, the executive vice president now owns 3,100 shares in the company, valued at approximately $992,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 27.84% of the company’s stock.

A number of research firms have issued reports on BIO. Barclays increased their target price on shares of Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 1st. ValuEngine upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. Deutsche Bank increased their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Goldman Sachs Group upgraded shares of Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 target price for the company in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $378.33.

BIO stock traded up $2.92 during midday trading on Wednesday, reaching $343.40. The company had a trading volume of 29,368 shares, compared to its average volume of 232,860. The company has a 50 day moving average of $319.34 and a two-hundred day moving average of $300.90. Bio-Rad Laboratories, Inc. has a 1 year low of $220.05 and a 1 year high of $344.77. The company has a market capitalization of $9.76 billion, a P/E ratio of 58.80, a PEG ratio of 3.04 and a beta of 1.21. The company has a current ratio of 4.68, a quick ratio of 3.36 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported $1.57 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.18. Bio-Rad Laboratories had a net margin of 39.32% and a return on equity of 3.92%. The company had revenue of $572.60 million for the quarter, compared to analyst estimates of $564.88 million. During the same quarter in the prior year, the business posted $1.64 EPS. Bio-Rad Laboratories’s quarterly revenue was down .6% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 7.19 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: What does a neutral rating on stocks mean?

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.